Copper Cu 64 PSMA I&T
Phase 3Small molecule
Copper Cu 64 PSMA I&T is one of 29 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1399 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Novantrone
PfizerPreclinical
Copper Cu 64 PSMA I&T
CCurium US LLC
Phase 3
Mekinist
NovartisPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Viagra
VViatris Specialty LLC
Preclinical
Duragesic
CCephalon
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Prednisone/prednisolone
RochePreclinical
Triptorelin Pamoate
IpsenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Copper Cu 64 PSMA I&T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCurium US LLC